Presentation is loading. Please wait.

Presentation is loading. Please wait.

Universal Pharmacare: Solving Canada’s Drug Problem Pharmacare Forum Windsor Public Library, April 26, 2011 Canadian Health Coalition.

Similar presentations


Presentation on theme: "Universal Pharmacare: Solving Canada’s Drug Problem Pharmacare Forum Windsor Public Library, April 26, 2011 Canadian Health Coalition."— Presentation transcript:

1 Universal Pharmacare: Solving Canada’s Drug Problem Pharmacare Forum Windsor Public Library, April 26, 2011 Canadian Health Coalition

2 Canada’s Drug Problem 1. No ability to control costs, rising 10.5% a year 2.Drug are overpriced – Canada 3 rd highest in world 3.8 million Canadians uninsured or underinsured 4.Prescription drug over-use and misuse especially with children and the elderly 5.New drugs rushed to market based on secret, dubious data. Rx drugs are 4 th leading cause of death

3 Pharma’s 7 Deadly Sins 1. Conducts unethical clinical trials 2.Ghost-writes studies, hides negative results and promotes illegal off-label use to doctors 3.Bribes doctors, pharmacists and medical researchers 4.Advertises hazardous drugs with misleading information 5.Invents illnesses in order to sell more drugs 6.Buys silence from regulators and politicians 7.Prevents the poor from getting medicines

4 Illegal off-label promotion to MD’s

5 Big Pharma Profits compared to Fortune 500 firms (1954-2008; in millions of constant 1984 US$) Source: Fortune

6 Dominant Business Model: massive promotion of ‘me-too’ drugs & control over Medical Knowledge Sales: $239.8 billion R&D: $24.1 billion (10% of revenues) Promotion: $57.5 billion (24.4% of revenues) Promotion directed towards physicians: $42.8 billion Average promotion spending per physician: $61,000 1 drug rep for every 6 physicians Undisclosed promotion: Fellowships, ghostwriting, « off-label », seeding trials, astro-turf groups… Merck made $12.9 billion in 2009 and then closed its research lab in Montreal (180 jobs lost)

7 Retail price for an identical volume of pharmaceutical products OECD countries, 2005 (US$, market exchange rate) Source: OECD 2008 - Eurostat OECD PPP Programme, 2007.

8 Most New Drugs Have No Significant Advantage CategoryPercent Nothing new51% Possibly helpful21% Harmful14% Offers an advantage7% Judgement reserved5% A real advance2% Major breakthrough0.2% Total100.0 Source: France 2001-2010, Préscrire International, 2011

9 Direct-to-consumer-advertising Drives up prescription drugs costs Fails to inform Compromises public safety: exposure to dangerous drugs before risks are fully recognized, Additionally, most new drugs are costlier than existing treatments, but few provide any therapeutic advantage. Promotes the medicalisation of normal life

10 The Economic Case for Universal Pharmacare

11 Pharmacare Savings - A Current expenditure on prescription drugs $ 25.141B Growth in expenditures from increased use +10% Reduction from decrease in dispensing fees - 2% Reduction from drug assessment - 8% Elimination of the monthly deductible in Qc $144M Elimination of rebate system for generics$1.3B Elimination of the 15-year rule in Quebec $102M Change PMPRB price fixing$1.43B Elimination of extra costs for private plans $560M Elimination of tax subsidies$933M Total net savings annually $ 4.479B

12 Pharmacare Savings - B Savings from competitive purchasing $10.2 B Growth in expenditures from increase in use +10% Reduction from decrease in dispensing fees -2% Elimination of the deductible in Qc$ 144M Elimination of the 15-year rule in Quebec$102M Elimination of extra costs of private plans$ 560M Elimination of tax subsidies$ 933M Total savings annually $ 10.744 Billion

13 Industrial Policies = Total Failure Innovation policies are justified by the multiplying effect on the benefits it creates as compared to costs. With a negative multiplying effect, innovation policies in the pharmaceutical sector are a total failure: Canada spends $7.4 billion in subsidies Value-added in return is only $4.8 billion

14 Rx spending up 73.7% CANADA,1999-2009, per capita, inflation adjusted

15 Public spending is stable

16 Replace our patchwork U.S.-style drug insurance plans with universal, first-dollar coverage (no deductible or co-pay) Pay only for drugs that have been independently established to be safe and cost-effective Establish a National formulary End the price-fixing and public subsidies of Big Pharm Start bulk purchasing www.PharmacareNow.ca Universal Pharmacare will save $ billions

17 Pay for What Works

18 Next steps for Canadians “Democracy is the thing that lets ordinary people do extraordinary things. There isn’t anything we can’t accomplish if we set our minds to it.” - Tommy Douglas


Download ppt "Universal Pharmacare: Solving Canada’s Drug Problem Pharmacare Forum Windsor Public Library, April 26, 2011 Canadian Health Coalition."

Similar presentations


Ads by Google